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Introduction
Fresh frozen plasma (FFP) is a blood product that has been 
available since 1941 [1]. Initially used as a volume expander, 
it is currently indicated for the management and prevention 
of bleeding in coagulopathic patients [1-3]. Th   e evidence on 
FFP transfusion is scant and of limited quality [4].
Estimates state that 25 to 30% of all critical care 
patients receive FFP transfusions [5,6]. Despite its com-
mon  ality, only 37% of the physicians in a recent study 
correctly responded to basic questions about FFP, includ-
ing the volume of one unit [7]. An audit on transfusion 
practices suggested that one-half of all FFP transfused to 
critical care patients is inappropriate [5].
Massive haemorrhage is among the most challenging 
issues in critical care, aﬀ  ecting trauma patients, surgical 
patients, obstetric patients and gastrointestinal patients 
[3,8,9]. In trauma, a recent series of retrospective clinical 
studies suggests that early and aggressive use of FFP at a 
1:1 ratio with red blood cells (RBC) improves survival in 
cases of massive haemorrhage [10-19]. Because bleeding 
is directly responsible for 40% of all trauma-related 
deaths, this strategy – also known as haemostatic damage 
control or formula-driven resuscitation – has received 
substantial attention worldwide. Th  is early formula-
driven haemostatic resuscitation proposes transfusion of 
FFP at a near 1:1 ratio with RBC, thus addressing 
coagulo  pathy from the beginning of the resuscitation and 
potentially reducing mortality. Nevertheless, this strategy 
requires immediate access to large volumes of thawed 
universal donor FFP, which is challenging to implement.
Despite conﬂ  ict with existing guidelines, early formula-
driven haemostatic resuscitation use is expanding and is 
gradually being used in nontraumatic bleedings in critical 
care [20]. Both the existing guidelines and early formula-
driven haemostatic resuscitation are supported by limited 
evidence, generating controversies and challeng  ing clinical 
decisions in critical care (Table 1). Th  e objective of the 
present article is to review the evidence on FFP in the 
management of massive traumatic haemor  rhage and to 
critically appraise early formula-driven haemostatic 
resuscitation, providing the reader with resources to 
develop an informed opinion on the current controversy.
Plasma basics
‘Fresh frozen plasma’ is a confusing term as plasma 
cannot be fresh and frozen at the same time. Fresh refers 
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© 2010 BioMed Central Ltdto timing from collection to freezing, and frozen refers to 
the long-term storage condition. FFP transfusion must be 
ABO compatible, with AB being the universal type, 
lacking anti-A and anti-B antibodies. Only 4% of the 
popu  lation is AB, resulting in chronic shortage of this 
blood type [21].
Preparation and composition
FFP is prepared from either single units of whole blood (a 
whole blood-derived unit is approximately 250  ml) or 
plasma collected by apheresis (usually 500 ml) [1,2,22]. 
FFP is collected in citrate-containing anticoagulation 
solution, frozen within 8 hours and stored at –30°C for 
up to 1  year. FFP contains all of the clotting factors, 
ﬁ  brino  gen (400 to 900 mg/unit), plasma proteins (par-
ticularly albumin), electrolytes, physiological anticoagu-
lants (protein C, protein S, antithrombin, tissue factor 
pathway inhibitor) and added anticoagulants [1,2].
Plasma frozen within 24 hours of collection is termed 
frozen plasma (PF24), containing 15 to 20% lower factor 
VIII levels than FFP [23,24]. PF24 is common in countries 
using the buﬀ  y-coat method, in which RBC and plasma 
are extracted after hard spin from whole blood and 
platelets recovered after a second soft spin within 
24 hours of collection. PF24 has similar clinical indica-
tions as FFP [2,23,24].
FFP is commonly thawed in a water bath over 20 to 
30  minutes, but US Food and Drug Administration-
approved microwaves can thaw 2 units of plasma in 2 to 
3 minutes [1]. After thawing, the activity of labile clotting 
factors such as factor V and factor VIII decline gradually, 
and most countries recommend FFP use within 24 hours 
[25,26]. In some countries, FFP is used up to 5 days after 
thawing. Th   e consequences of transfusing stored, thawed 
5-day-old plasma is not completely understood, but the 
activity of factor VIII is expected to drop by >50%, and 
the activity of factor V and factor VII drops to about 20% 
5 days after thawing [27].
Photochemically treated FFP and solvent detergent FFP 
are approved methods of inactivating pathogens in some 
jurisdictions. Both methods cause loss of clotting factors, 
particularly factor VIII. Some solvent detergent FFP 
prepara  tions have reduced activity of protein S and 
α2-antiplasmin, and have been associated with thrombo-
embolic complications [28,29]. Th  ese solvent detergent 
preparations are extensively used in some European 
countries, while solvent detergent FFP was withdrawn in 
North America due to concerns of Parvovirus 
transmission [1].
Risks
FFP can transmit infectious diseases, albeit rarely. 
Screen  ing and pathogen inactivation reduced trans-
mission rates of HIV to 1:7.8 million, of hepatitis C virus 
to 1:2.3 million and of hepatitis B virus to 1:153,000 units 
transfused [30]. In the UK, concerns over Creutzfeldt–
Jakob disease – a rare but rapidly progressive spongiform 
encephalopathy – led to leukocyte depletion in all blood 
products and recom  mendations to use FFP from areas of 
low epidemicity [31,32].
Other important complications relate to blood 
immunogenicity, increasingly recognized over the past 
two decades, particularly transfusion-related acute lung 
injury (TRALI) and transfusion-associated circulatory 
overload [33,34]. TRALI is the commonest cause of 
transfusion-related death [33,34]. Two mechanisms have 
mostly been implicated in TRALI. Donor plasma 
antibodies react with human leukocyte antigens, causing 
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Table 1. Arguments for and against the adoption of early formula-driven haemostatic resuscitation in trauma
 Pros  Cons
Mortality  Retrospective studies suggesting a reduction in mortality   Data limited by survivorship bias
 from  exsanguination
    Increase in FFP and platelet use might increase the risk of acute 
    lung injury, multiple organ failure, thrombosis, sepsis and death
Coagulopathy  Prevention and treatment of coagulopathy due to   Diffi   cult to identify patients early on who will develop
  transfusion of clotting factors  coagulopathy and in fact need transfusion of FFP and platelets
  Minimize crystalloid use (decrease the risk of dilution)  Uncertainty about the ideal dose of FFP in the trauma situation
Laboratory tests  No need for coagulation tests  Unnecessary exposure to AB plasma (in some countries, a higher 
    risk of transfusion-related acute lung injury due to higher 
  Avoid the delay of waiting for blood test results  proportion of female donors)
Blood bank systems  More timely issuing of blood components  The waste of FFP will increase (shortage of AB plasma)
  No time needed to thaw FFP (AB plasma available at all times)  May increase the complications associated with FFP and platelet 
   transfusion
  Decrease the need for communication between blood bank 
  and the medical team 
FFP, fresh frozen plasma.
Page 2 of 8complement activation, endothelial damage, neutrophil 
activation and lung capillary leak. Anti-human leukocyte 
antigens and anti-neutrophil antibodies are commonly 
found in plasma from multiparous female donors, and 
the TRALI frequency is higher in recipients from female 
donors [35-37]. To minimize the risk of TRALI, a male-
only plasma policy has been adopted in many countries – 
with marked reductions in TRALI [35]. Another potential 
mechanism involves interactions of biologically active 
mediators in stored plasma and lung endothelial cells. 
Other important transfusion-related complications 
include acute haemolytic reaction from anti-A and anti-B 
antibodies, and anaphylaxis [22].
Massive bleeding
Massive bleeding is deﬁ   ned as the loss of one blood 
volume within 24 hours, or as 50% blood loss within 
3 hours or a bleeding rate of 150 ml/minute [38]. Th  e 
physiological derangements and complications are pro-
por  tional to the blood loss and to the time to correct 
shock. Loss of one blood volume and replacement with 
RBC only results in clotting factor levels dropping to 
approximately 30%, the minimal level thought to be 
required for adequate haemostasis [3,39]. Lower levels 
signiﬁ   cantly prolong the prothrombin time and the 
activated partial thromboplastin time above 1.5x normal 
[1]. FFP transfusion to replace clotting factors is often 
recommended for these patients but no studies exist 
supporting this practice [4]. Replacing one blood volume 
or more without FFP results in dilutional coagulopathy, 
diﬀ  use microvascular bleeding and increased mortality 
[40,41].
Current guidelines for FFP in massive bleeding
Th   e principles of managing massive haemorrhage include 
rapid control of bleeding; replenishing the intravascular 
volume with crystalloid followed by RBC and, once 
coagulopathy is present or suspected, then adding FFP, 
platelets and cryoprecipitate; along with correction of 
acidosis and hypothermia. Most current guidelines 
[1,39,42-44], including the European and US guidelines, 
recommend transfusing FFP, platelets and cryoprecipitate 
only when laboratory assays detect a deﬁ  cit. Th   e goal is 
to correct the assays as follows: FFP to correct the 
prothrombin time/activated partial thrombo  plastin time 
to <1.5x normal, platelets to raise the count to ≥50 x 109/l 
and cryoprecipitate to raise ﬁ  brinogen to ≥1.0 g/l [1,42-
44]. Where a laboratory is not available, these products 
are recommended after large infusions of crystalloid and 
RBC. Th   e usual FFP dose in massive bleeding is 15 to 20 
ml/kg or 3 to 6 units, which aims to raise clotting factors 
levels above 30% [3,38,39].
Current crystalloid-based resuscitation guidelines 
initiate FFP transfusion late, often after more than one 
blood volume is lost and the patients have clinically overt 
coagulopathy [40,41]. Most recommendations are based 
on observations and expert opinion, often lacking high-
level evidence. Many recommendations originated in 
studies conducted in nontrauma settings and when RBC 
units had 150 to 300  ml plasma [1]. Currently, RBC 
preparations contain only minimal residual plasma 
(≤30  ml). Despite worldwide acceptance of similar 
resuscitation principles, bleeding remains the second 
overall cause of death in trauma – becoming the ﬁ  rst 
cause of death following hospital admission [45-47].
Trauma-associated coagulopathy
Haemorrhage is directly responsible for 40% of all 
trauma-related deaths [45,46], and many deaths are 
potentially preventable. Current resuscitation strategies 
invariably fail to prevent coagulopathy in massive 
bleedings. Multiple causes have traditionally been impli-
cated in trauma coagulopathy, including clotting factor 
consumption and dilution, hypothermia and acidosis – 
all linked to large-volume crystalloid infusion and late 
replacement of clotting elements [40,41]. Th  e manage-
ment of massive trauma bleeding started changing when 
Brohi and MacLeod and colleagues separately described 
that trauma coagulopathy occurs early, and is present on 
hospital admission in 25% of all severely traumatized 
patients [48,49]. Further studies suggest that early 
coagulo  pathy is initiated by shock and the amount of 
tissue destruction, independent of clotting factor 
consumption or dilution (Figure  1), and is associated 
with a threefold mortality increase [48,49].
A unique coagulopathy in traumatic brain injury has 
long been suspected, where the release of brain tissue 
factor causes systemic activation of coagulation (dissemi-
nated intravascular coagulation), exhaustion of clotting 
elements and hyperﬁ  brinolysis [50,51]. While coagulo-
pathy is common and critically important in traumatic 
brain injury, the controversial existing evidence suggests 
it may not diﬀ  er from trauma coagulopathy in general 
[51].
Th   e early trauma coagulopathy concept has challenged 
the current crystalloid-based resuscitation that ignores 
coagulopathy until it becomes overt. Over the past 
2 years, a haemostatic blood-based resuscitation – com-
monly termed damage control resuscitation – proposes a 
series of early and aggressive strategies to treat or prevent 
early trauma-associated coagulopathy [52,53]. Th  is 
resuscitation entails the use of thawed plasma as the 
primary resuscitation ﬂ   uid, limited use of crystalloid, 
targeted systolic blood pressure at approxi  mately 
90 mmHg to prevent renewed bleeding, early activation 
of a massive transfusion protocol with ﬁ  xed ratios of FFP:
platelets:cryoprecipitate:RBC (approxi  mately 1:1:1:1), 
liberal use of recombinant activated factor VII (rFVIIa) 
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injured combat casualties [52,53].
Critical appraisal of the evidence on early formula-
driven haemostatic resuscitation
Th  e ﬁ  rst reports suggesting aggressive FFP transfusions 
were computer simulation models. In 2003, Hirshberg 
and colleagues published a haemodilution model of 
exsanguination, calculated the changes in coagulation 
and predicted an optimal FFP:RBC ratio of 2:3 to ade-
quately replenish clotting factors [54]. Ho and colleagues 
predicted 1 to 1.5 units FFP to each RBC to prevent 
dilutional coagulopathy in mathematical models [55].
Since 2007, growing numbers of retrospective military 
and civilian papers have studied early formula-driven 
haemostatic resuscitation with diﬀ  erent FFP:RBC ratios 
(mostly near 1:1) and mortality [11-20,56,57]. Overall, 
these studies demonstrate a signiﬁ  cant  association 
between higher ratios and lower mortality in massive 
traumatic bleedings, with absolute mortality reductions 
ranging between 15 and 62% [11-20]. Th  ese ﬁ  gures 
surpass any predictions of potentially preventable deaths 
in trauma [47]. While the survival advantage of early and 
aggressive FFP transfusion in early formula-driven 
resuscitation cannot be ignored, the evidence behind it 
has limitations that are discussed next.
Survival advantage
Borgman and colleagues reviewed 246 massively trans-
fused (≥10 units RBC/24 hours) combatants and analysed 
mortality at three diﬀ  erent FFP:RBC ratios (1:8, 1:2.5 and 
1:1.4) [11]. A 55% absolute reduction in mortality 
occurred between the highest and lowest ratios. While 
mortality reduction was impressive, patients with a 
higher FFP:RBC ratio (1:1.4) had a longer median time to 
death (38 hours) than those with a lower ratio (2 hours). 
Th   ese data suggest that lower ratio patients may not have 
lived long enough to receive FFP. Another study by the 
same group on civilian trauma patients reported a 
similarly impressive survival advantage for higher ratios 
than lower ratios, but also a markedly dissimilar time to 
death (35 hours versus 4 hours) [58]. Both studies disclose 
survivorship bias, where arguably patients had to survive 
long enough to receive FFP, thus questioning their 
conclusions.
Addressing survivorship bias
Two studies speciﬁ  cally addressed the survivorship bias 
in high-FFP:RBC studies. Scalea and colleagues used 
stepwise logistic regression analysis on 806 patients, 
demonstrating no survival beneﬁ  t for higher ratios when 
early deaths were excluded [56]. Th  is study has its own 
limitations, however, including a failure to report the 
time to intensive care unit admission, an inability to 
include major factors (acidosis and coagulation) in the 
statistical model and a surprisingly low mortality (6%) for 
massive transfusions. Snyder and colleagues also attemp-
ted to correct for survivorship bias in another study 
where mortality in high (>1:2) and low (<1:2) ratios was 
compared in regression models [57]. Using the FFP:PRBC 
ratio as a ﬁ  xed value at 24 hours, as in many studies on 
this topic, the high ratio resulted in better survival. Th  is 
survival advantage was lost, however, when the ratio was 
treated as a time-dependent variable (relative risk = 0.84, 
95% conﬁ  dence interval = 0.47 to 1.5). Th   ese two studies 
dispute the survival advantage suggested by the previous 
studies with such bias.
Time to intervention
Th  e delay to thaw and initiate FFP transfusion leads to 
another important limitation: timing to initiate and reach 
the high FFP:RBC ratio. Early formula-driven resusci-
tation proposes that FFP should be initiated early, ideally 
with the ﬁ   rst RBC unit at the start of resuscitation 
[52,53]. Considering that even laboratory-guided resusci-
tation eventually results in a high FFP:RBC ratio, a 
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Figure 1. Recently proposed mechanism for coagulopathy 
in trauma. Tissue trauma activates the coagulation process via 
tissue factor (TF) and activated factor VII (FVIIa), formerly named 
the extrinsic pathway, to stop bleeding. Concomitantly, endothelial 
damage/ischaemia leads to release of physiologic anticoagulants 
and antifi  brinolytics (that is, thrombomodulin (TM), protein C 
and tissue plasminogen activator (tPA)) due to infl  ammation and 
tissue hypoperfusion, to prevent thrombosis. Early coagulopathy 
develops when there is an imbalance in this process, with excessive 
anticoagulation, hyperfi  brinolysis and consumption of clotting 
factors. Resuscitation with crystalloid and red blood cells (RBC) can 
cause/worsen dilution, acidosis and hypothermia. PAI-1, plasminogen 
activator inhibitor 1.
Page 4 of 8critical diﬀ  erence in formula-driven resuscitation is the 
early implementation of a high ratio. No studies to date 
have reported on transfusing pre-thawed FFP along with 
the ﬁ  rst RBC units or on the time to reach the 1:1 ratio. 
Snyder and colleagues stated that the median time to the 
ﬁ  rst RBC was 18 minutes from arrival, while the ﬁ  rst FFP 
was transfused more than 1 hour later [57].
Th  e commonly used deﬁ  nition of massive bleeding as 
transfusions over 24 hours ignores the fact that 80% of all 
massive transfusions occur within the ﬁ   rst 6 hours of 
hospitalization, at which point either bleeding reduces 
substantially or the patient dies [59]. A multicentre study 
involving 16 trauma centres, 452 massively bleeding 
trauma patients and transfusion rates within 6 hours of 
hospitalization (rate <1:4, rate of 1:4 to 1:1 and rate ≥1:1) 
concluded that early high FFP:RBC and platelet:RBC ratios 
improved survival [19]. Despite limitations, including 
signiﬁ    cant diﬀ  erences in the baseline Glasgow coma scale 
and therefore the severity of head injuries between groups, 
the study provides better evidence that reaching high 
FFP:platelet:RBC ratios within the ﬁ  rst hours of admission 
is associated with mortality reduction.
Missing data, co-interventions and heterogeneity
Data on timing to initiate FFP transfusions, on timing to 
reach the 1:1 ratio and on transfusions during the ﬁ  rst 6 
hours are equally missing in the studies supporting early 
formula-driven haemostatic resuscitation and in existing 
guidelines, limiting comparisons between the diﬀ  erent 
strategies.
Spinella and colleagues reported in 708 military 
patients transfused with ≥1 units RBC that FFP 
transfusion was associated with increased survival (odds 
ratio = 1.17, 95% conﬁ   dence interval = 1.06 to 1.29; 
P  =  0.002) [12]. Missing data on the International 
Normalized Ratio, not measured in one-half of the 
patients, and heterogeneity with nonsurviving patients 
being signiﬁ   cantly more coagulopathic than that for 
surviving patients, International Normalized Ratio 2.06 
versus 1.4 (P <0.001) on admission, however, challenge 
their con  clusion.
Aggressive and early FFP transfusion is part of damage 
control resuscitation, which also proposes crystalloid 
restriction, rFVIIa and other interventions. A small study 
on 40 combat casualties resuscitated with a package 
containing whole blood, rFVIIa, crystalloid restriction 
and a high FFP:RBC ratio illustrates the complexity of 
analysing multiple co-interventions [52]. Combatants 
receiving the package had better survival compared with 
historical controls managed with similar FFP:RBC ratios 
but not rFVIIa, whole blood and signiﬁ  cantly less blood 
transfusion [60]. In this study, multiple co-interventions 
make it impos  sible to establish the contribution of any of 
them.
Two other studies analysed survival before and after 
implementation of massive transfusion protocols [13,17]. 
Both studies demonstrated better survival with the 
protocol despite no diﬀ  erence in 24-hour FFP transfusion 
before and after protocol implementation and despite 
FFP:RBC ratios other than 1:1. Th  e results could be 
interpreted as the protocol, and not the high FFP:RBC 
ratios, leading to better survival.
Potential harm
In a study demonstrating the survival advantage of 
aggressive FFP transfusion in the intensive care unit, 
Gonzalez and colleagues reported an unusual high 
incidence of early and lethal acute respiratory distress 
syndrome [10]. Th   e aggressive FFP transfusion was aimed 
at correcting the International Normalized Ratio to ≤1.3, 
probably an unattainable goal given that the International 
Normalized Ratio of FFP is near 1.3 [61-63]. Considering 
that the deaths might represent transfusion-associated 
circulatory overload or TRALI, the study raises concerns 
on the aggressive FFP transfusion strategy. In a separate 
study of 415 trauma patients [64], early acute respiratory 
distress syndrome (before day 4) occurred signiﬁ  cantly 
more among those patients transfused more FFP. Some 
studies, however, suggest that the adoption of early and 
aggressive FFP transfusion in fact reduces the overall 
exposure to blood and blood products [19]. Here also, the 
evidence is conﬂ   icting and precludes deﬁ  nitive 
conclusions.
Ethical and logistical considerations
In many countries, blood transfusion requires written 
informed consent, which is deferred only in life-
threatening situations, including massive bleeding. Th  e 
proposal to transfuse FFP early and aggressively raises 
important ethical considerations. First, traumatic massive 
bleeding carries upm to 40% mortality even when current 
resusci  tation guidelines are strictly followed, and early 
coagulopathy increases mortality threefold. Th  e marked 
reduction in mortality recently reported with early and 
high FFP:RBC resuscitation has prompted many trauma 
centres to adopt this strategy. Th   e evidence behind early 
formula-driven haemostatic resuscitation is concordant 
with recent advances in the understanding of early 
trauma coagulopathy, but they also have methodological 
ﬂ  aws and bias that seriously question the survival beneﬁ  t.
Many trauma centres keep thawed AB plasma (uni-
versal donor) available at all times for resuscitation. In 
countries that have implemented policies favouring male-
only plasma to minimize the risks of TRALI, supplying 
AB plasma becomes an even greater challenge. Other 
ethical, logistical and ﬁ  nancial considerations include the 
potential waste of unused thawed FFP, a so far untouched 
issue, plus the ﬁ  nancial costs of haemostatic protocols, 
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increased risk from exposure to female FFP).
Th   e answer to these challenges is not readily available 
or intuitive, particularly contrasting with the high 
mortality and lack of evidence supporting the existing 
guidelines. For now, the clinical decision continues to be 
based on observations, judgement and evidence trans-
planted from other ﬁ  elds. Deﬁ  nitive answers will only 
come from better understanding the pathophysiology of 
coagulation and prospective clinical trials, which may be 
years away. Th  e challenges to such clinical trials are 
summarized in Table 2.
Conclusion
Th   e current knowledge regarding coagulopathy and FFP 
precludes the development of evidence-based guidelines. 
Existing guidelines for the management of massive 
bleeding recommend late FFP transfusion, based on 
conventional coagulation assays, which correlate poorly 
with clinically bleeding.
Early formula-driven haemostatic resuscitation has 
challenged this approach and has proposed early and 
aggressive FFP transfusion at a FFP:RBC ratio near 1:1, 
thus treating or preventing early trauma coagulopathy. 
Initial studies have reported signiﬁ   cant reductions in 
mortality, but are uncontrolled and methodologically 
ﬂ   awed, particularly by survivorship bias. Presently, 
clinical decisions should be based in assessing the pros 
and cons of both strategies while considering local 
resources and individual clinical context.
Prospective clinical trials are urgently needed to 
determine whether early formula-driven haemostatic 
resuscitation should be adopted or forgotten, to better 
understand trauma-associated coagulopathy and to 
Table 2. Challenges and proposed solutions to future clinical trials on haemostatic resuscitation
Most important challenges  Proposed solutions
Avoid survivorship bias  Exclude patients not expected to live long enough to receive plasma
  Precise documentation of the time of transfusions and death
  Perform analysis of transfusion as a time-dependent variable
Avoid contamination of the control arm and avoid   Transfusion guidelines for both arms clear and easy to follow
delay in initiating 1:1 transfusions in the intervention arm
  Close cooperation between blood bank, trauma, anaesthesia and critical care
  Thawed AB plasma 24/7 or rapid thawing (microwave)
  Minimize time for results of laboratory tests – consider point-of-care testing
Multiple interventions concomitantly tested  Standardize all aspects of resuscitation (that is, amount and type of intravenous fl  uid; procoagulant 
  drugs) in control and intervention groups
  Measure clotting factor levels
Discriminate coagulopathic from mechanical bleeding  Measure indicators of coagulopathy:
 •  Thromboelastography
  •  Clotting factor assays
  •  Markers of hyperfi  brinolysis
  •  Tissue hypoperfusion (lactate, base defi  cit)
  •  Progression of bleeding by computerized tomography scan (that is, progression brain 
    contusion, retroperitoneal haematomas)
  •  Ask the physician’s opinion (that is, surgeon, anaesthetist, intensivist)
Immediate cessation of component therapy  Evidence that bleeding has stopped
  Consider ending by 6 hours
Outcome  Consider restoration of haemostasis competence
Need for large samples  Consider a feasibility trial prior to a large multicentre trial to identify major challenges
Consent  Need for delayed consent
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Other areas for future research include improving the 
diagnosis of coagulopathy and evaluating novel products 
such as thawing microwaves for faster release of blood 
products.
Abbreviations
FFP = fresh frozen plasma; RBC = red blood cells; rFVIIa = recombinant factor 
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